Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA19 Feb 2008Cited by 12 (Europe PMC)

PMID18283386DOI10.1007/s00198-007-0557-zPepBankPUB-18283386

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialSafety outcome
In women continuing alendronate, adding teriparatide did not significantly change predose mean serum calcium.
In plain wordsAdding teriparatide to alendronate did not significantly change mean predose calcium compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePredose calcium with added teriparatide and alendronate
Study
n = 52
Comparator
Baseline
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 microg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
Predose mean serum Ca did not significantly change in groups adding TPTD to either RLX or ALN treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 6-month treatment with teriparatide (20 microg/day; rhPTH(1-34), TPTD) on serum calcium (Ca) was examined in a prospective study of postmenopausal women previously treated with alendronate (70 mg/week or 10 mg/day [ALN] or raloxifene 60 mg/d [RLX]) for > or =18 months.
Summary · context
Women previously treated with ALN were randomized to add TPTD (n = 52) or switch to TPTD (n = 50) and women previously treated with RLX were randomized to add TPTD (n = 47) or switch to TPTD (n = 49).
Report a problemFND-1828338602
02HumanRandomized controlled trialSafety outcome
In women who switched from alendronate to teriparatide, mean serum calcium increased by 0.04 mmol/L.
In plain wordsMean calcium increased compared with baseline after women switched from alendronate to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePredose calcium after switching from alendronate
Study
n = 50
Comparator
Baseline
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 microg/day · 6 monthsAs given in this study (human).
Measurements
Change in mean predose serum calcium
0.04 mmol/L
switched from alendronate to teriparatide
Source sentences
Summary
In patients who switched from RLX or ALN to TPTD, mean serum Ca increased by 0.05 mmol/L and 0.04 mmol/L respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 6-month treatment with teriparatide (20 microg/day; rhPTH(1-34), TPTD) on serum calcium (Ca) was examined in a prospective study of postmenopausal women previously treated with alendronate (70 mg/week or 10 mg/day [ALN] or raloxifene 60 mg/d [RLX]) for > or =18 months.
Summary · context
Women previously treated with ALN were randomized to add TPTD (n = 52) or switch to TPTD (n = 50) and women previously treated with RLX were randomized to add TPTD (n = 47) or switch to TPTD (n = 49).
Report a problemFND-1828338604
03HumanRandomized controlled trialSafety outcome
In women who switched from raloxifene to teriparatide, mean serum calcium increased by 0.05 mmol/L.
In plain wordsMean calcium increased compared with baseline after women switched from raloxifene to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePredose calcium after switching from raloxifene
Study
n = 49
Comparator
Baseline
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 microg/day · 6 monthsAs given in this study (human).
Measurements
Change in mean predose serum calcium
0.05 mmol/L
switched from raloxifene to teriparatide
Source sentences
Summary
In patients who switched from RLX or ALN to TPTD, mean serum Ca increased by 0.05 mmol/L and 0.04 mmol/L respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 6-month treatment with teriparatide (20 microg/day; rhPTH(1-34), TPTD) on serum calcium (Ca) was examined in a prospective study of postmenopausal women previously treated with alendronate (70 mg/week or 10 mg/day [ALN] or raloxifene 60 mg/d [RLX]) for > or =18 months.
Summary · context
Women previously treated with ALN were randomized to add TPTD (n = 52) or switch to TPTD (n = 50) and women previously treated with RLX were randomized to add TPTD (n = 47) or switch to TPTD (n = 49).
Report a problemFND-1828338603
04HumanRandomized controlled trialSafety outcome
In women continuing raloxifene, adding teriparatide did not significantly change predose mean serum calcium.
In plain wordsAdding teriparatide to raloxifene did not significantly change mean predose calcium compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePredose calcium with added teriparatide and raloxifene
Study
n = 47
Comparator
Baseline
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 microg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
Predose mean serum Ca did not significantly change in groups adding TPTD to either RLX or ALN treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 6-month treatment with teriparatide (20 microg/day; rhPTH(1-34), TPTD) on serum calcium (Ca) was examined in a prospective study of postmenopausal women previously treated with alendronate (70 mg/week or 10 mg/day [ALN] or raloxifene 60 mg/d [RLX]) for > or =18 months.
Summary · context
Women previously treated with ALN were randomized to add TPTD (n = 52) or switch to TPTD (n = 50) and women previously treated with RLX were randomized to add TPTD (n = 47) or switch to TPTD (n = 49).
Report a problemFND-1828338601

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
Across teriparatide addition and switching regimens, one woman exceeded the predefined calcium threshold at more than one visit.
In plain wordsAcross teriparatide addition and switching regimens, one woman repeatedly exceeded the predefined calcium threshold.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableRepeated elevated serum calcium across regimens
Study
n = 198
Outcome group
Adverse events · Endocrine and hormones
Measurements
Patients with serum calcium above 2.76 mmol/L at more than one visit
1 patients
all four teriparatide regimens combined
Source sentences
Summary
Only 1 patient had the predefined calcium endpoint of serum calcium > 2.76 mmol/L (11 mg/dL) at more than one visit.
1 context sentence(design, population, supporting numbers)
Summary · context
Women previously treated with ALN were randomized to add TPTD (n = 52) or switch to TPTD (n = 50) and women previously treated with RLX were randomized to add TPTD (n = 47) or switch to TPTD (n = 49).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1828338605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.